News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
257,858 Results
Type
Article (13589)
Company Profile (73)
Press Release (244196)
Section
Business (87726)
Career Advice (459)
Deals (15340)
Drug Delivery (59)
Drug Development (36536)
Employer Resources (49)
FDA (6221)
Job Trends (6189)
News (149671)
Policy (14018)
Tag
Academia (442)
Africa (314)
Allergies (11)
Alliances (23031)
ALS (10)
Alzheimer's disease (316)
Antibody-drug conjugate (ADC) (18)
Approvals (6206)
Arizona (29)
Artificial intelligence (35)
Asia (19552)
Australia (2522)
Bankruptcy (143)
Best Places to Work (4164)
Biosimilars (24)
C2C Services and Suppliers (10629)
California (294)
Canada (297)
Cancer (56)
Cardiovascular disease (11)
Career advice (402)
Cell therapy (17)
China (21)
Clinical research (29923)
Collaboration (24)
COVID-19 (756)
Cystic fibrosis (21)
Delaware (11)
Diabetes (10)
Diagnostics (1186)
Diversity, equity & inclusion (13)
Drug pricing (38)
Earnings (30844)
Employer resources (43)
Europe (38251)
Events (36075)
Executive appointments (14)
FDA (6237)
Florida (23)
Funding (13)
Gene editing (12)
Gene therapy (28)
GLP-1 (244)
Government (1253)
Healthcare (3502)
Hotbed/Location (178115)
Illinois (50)
Indiana (42)
Infectious disease (758)
Inflammatory bowel disease (39)
Interviews (58)
IPO (5761)
IRA (14)
Job creations (2050)
Job search strategy (375)
Kansas (45)
Layoffs (159)
Legal (3401)
Liver cancer (16)
Lung cancer (13)
Management (16)
Manufacturing (27)
Maryland (47)
Massachusetts (198)
Medical device (1254)
Medtech (1255)
Mergers & acquisitions (9457)
Metabolic disorders (65)
Neuroscience (349)
New Jersey (33)
New York (27)
NextGen Class of 2024 (1580)
Non-profit (595)
North Carolina (68)
Obesity (42)
Opinion (103)
Patents (21)
Pennsylvania (14)
People (28120)
Phase I (7794)
Phase II (12656)
Phase III (11381)
Podcasts (32)
Policy (23)
Postmarket research (1401)
Preclinical (3118)
Rare diseases (30)
Real estate (2625)
Recruiting (17)
Regulatory (9650)
Reports (12)
Research institute (568)
Resumes & cover letters (55)
South America (498)
Startups (1628)
Texas (27)
United States (969)
Vaccines (86)
Washington State (30)
Weight loss (38)
Date
Today (16)
Last 7 days (181)
Last 30 days (725)
Last 365 days (13703)
2024 (7749)
2023 (14256)
2022 (19613)
2021 (20159)
2020 (19077)
2019 (14943)
2018 (11755)
2017 (13932)
2016 (13156)
2015 (15486)
2014 (12439)
2013 (10604)
2012 (11402)
2011 (11929)
2010 (10891)
257,858 Results for "rocket pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info
Rocket Pharmaceuticals’ gene therapy Kresladi has been hit with an FDA Complete Response Letter requesting additional chemistry, manufacturing and controls information to complete its review.
June 28, 2024
·
2 min read
·
Tyler Patchen
Policy
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I).
June 28, 2024
·
8 min read
Business
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
May 6, 2024
·
12 min read
Pharm Country
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals, Inc. today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601.
May 29, 2024
·
7 min read
Pharm Country
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rocket Pharmaceuticals, Inc. announced longer-term data updates from its lentiviral vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy.
May 10, 2024
·
16 min read
Business
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced the appointment of Aaron Ondrey, as Chief Financial Officer, and the further evolution of its corporate leadership team through key appointments with existing team members
March 26, 2024
·
8 min read
Policy
FDA Pushes Back PDUFA Data for Rocket’s Gene Therapy for Rare Blood Disorder
Citing the need for more time to review additional Chemistry, Manufacturing and Controls information, the FDA has extended its target action date for Rocket Pharmaceuticals’ investigational gene therapy by three months.
February 14, 2024
·
2 min read
·
Tristan Manalac
Policy
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Rocket Pharmaceuticals, Inc. announced that the European Medicines Agency accepted the Marketing Authorization Application for RP-L102, its lentiviral vector-based investigational gene therapy for Fanconi Anemia, complementation group A, a rare genetic disorder caused by mutations in the FANCA gene affecting DNA repair and characterized by bone marrow failure, cancer predisposition, and congenital malformations.
April 2, 2024
·
9 min read
Business
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2023.
February 26, 2024
·
11 min read
Business
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Rocket Pharmaceuticals, Inc. today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.
December 12, 2023
·
6 min read
1 of 25,786
Next